Literature DB >> 24966933

Inhibitory role of prohibitin in human ovarian epithelial cancer.

Lin Jia1, Jian-Min Ren2, Yi-Ying Wang3, Yu Zheng4, Hui Zhang5, Qing Zhang5, Bei-Hua Kong5, Wen-Xin Zheng6.   

Abstract

OBJECTIVES: To characterize the exact individual roles of gonadotropins on ovarian epithelial carcinogenesis, an earlier study showed that prohibitin was significantly up-regulated by luteinizing hormone (LH). To further clarify the role of prohibitin in ovarian carcinogenesis and its association with LH, herein we studied the expression of prohibitin in various ovarian tissues including different developmental stages of ovarian epithelial tumors.
METHODS: A total of 135 samples were studied by immunohistochemistry. These included benign ovarian cases with follicles, ovarian surface epithelia and ovarian epithelial inclusions (OEI) (n=30), serous cystadenoma (n=14), serous borderline tumor (n=12), serous carcinoma (n=20), mucinous cystadenoma (n=10), mucinous borderline tumor (n=10), mucinous carcinomas (n=10), endometrioid carcinomas (n=12), poorly/undifferentiated carcinomas (n=5), and fallopian tube (n=12).
RESULTS: Strong and diffuse staining of prohibitin was detected in luteinized ovarian stromal cells, follicular cells, fallopian tube, and OEI with serous differentiation. A significantly higher prohibitin expression in luteinized stromal cells than in non-luteinized stromal cells was observed (P<.01). Within the ovarian epithelium, the level of prohibitin expression was basically negative in ovarian surface epithelia, but highly expressed in OEI. However, compared to the level of prohibitin expression in OEI, it showed a trend of gradual loss from benign ovarian tumors, to borderline tumors and to carcinomas (P<.0001). Compared to the serous tumors, epithelial tumors with mucinous differentiation showed a significant lower level of prohibitin (P<.0001). An inverse correlation was noted between prohibitin expression and cancer grade. It is interesting to note that a high prohibitin expression level was seen in the fallopian tube, which is similar to OEI.
CONCLUSIONS: These data further suggest that prohibitin plays a tumor suppressing role, which is probably associated with LH mediated protection role against ovarian epithelial carcinoma. In addition to the tumor suppressive role of prohibitin, it also plays a role in cellular differentiation, which may be helpful to differentiate ovarian mucinous tumors from the tumors with serous differentiation in clinical settings. More importantly, our findings are supportive that the ovarian epithelial cancers, particularly the serous cancers including those precursors with serous differentiation are likely to be derived from fallopian tube instead of ovarian surface epithelia.

Entities:  

Keywords:  Gonadotropin; luteinizing hormone; ovarian cancer; prohibitin

Mesh:

Substances:

Year:  2014        PMID: 24966933      PMCID: PMC4069900     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

Review 1.  Gonadotrophins and ovarian-follicular growth.

Authors:  J S Richards; R Farookhi
Journal:  Clin Obstet Gynaecol       Date:  1978-08

2.  Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone.

Authors:  W Zheng; J J Lu; F Luo; Y Zheng; Y j Feng; J C Felix; S C Lauchlan; M C Pike
Journal:  Gynecol Oncol       Date:  2000-01       Impact factor: 5.482

Review 3.  The distal fallopian tube: a new model for pelvic serous carcinogenesis.

Authors:  Christopher P Crum; Ronny Drapkin; Alexander Miron; Tan A Ince; Michael Muto; David W Kindelberger; Yonghee Lee
Journal:  Curr Opin Obstet Gynecol       Date:  2007-02       Impact factor: 1.927

4.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.

Authors:  J M Piek; P J van Diest; R P Zweemer; J W Jansen; R J Poort-Keesom; F H Menko; J J Gille; A P Jongsma; G Pals; P Kenemans; R H Verheijen
Journal:  J Pathol       Date:  2001-11       Impact factor: 7.996

5.  Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study.

Authors:  H A Risch; L D Marrett; M Jain; G R Howe
Journal:  Am J Epidemiol       Date:  1996-08-15       Impact factor: 4.897

6.  Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract.

Authors:  Wenjun Cheng; Jinsong Liu; Hiroyuki Yoshida; Daniel Rosen; Honami Naora
Journal:  Nat Med       Date:  2005-04-10       Impact factor: 53.440

7.  Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer.

Authors:  J J Lu; Y Zheng; X Kang; J M Yuan; S C Lauchlan; M C Pike; W Zheng
Journal:  Gynecol Oncol       Date:  2000-11       Impact factor: 5.482

Review 8.  The role of luteinizing hormone in folliculogenesis and ovulation induction.

Authors:  M Filicori
Journal:  Fertil Steril       Date:  1999-03       Impact factor: 7.329

Review 9.  Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause.

Authors:  Jurgen M J Piek; Peter Kenemans; René H M Verheijen
Journal:  Am J Obstet Gynecol       Date:  2004-09       Impact factor: 8.661

10.  Secretory cell expansion with aging: risk for pelvic serous carcinogenesis.

Authors:  Jie Li; Yan Ning; Nisreen Abushahin; Zeng Yuan; Yiying Wang; Yue Wang; Bingbing Yuan; Janiel M Cragun; Setsuko K Chambers; Kenneth Hatch; Beihua Kong; Wenxin Zheng
Journal:  Gynecol Oncol       Date:  2013-09-20       Impact factor: 5.482

View more
  2 in total

Review 1.  Prohibitin - At the crossroads of obesity-linked diabetes and cancer.

Authors:  Suresh Mishra; Bl Grégoire Nyomba
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-11

2.  Cytokines and Prognostic Factors in Epithelial Ovarian Cancer.

Authors:  Millena Prata Jammal; Agrimaldo Martins-Filho; Thales Parenti Silveira; Eddie Fernando Candido Murta; Rosekeila Simões Nomelini
Journal:  Clin Med Insights Oncol       Date:  2016-08-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.